Matches in SemOpenAlex for { <https://semopenalex.org/work/W2531935797> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2531935797 endingPage "090" @default.
- W2531935797 startingPage "086" @default.
- W2531935797 abstract "Aim of the Study mTOR inhibitors are showing promising results in the management of vascular anomalies. Although current controlled trials remain to be completed, many individual experiences are being published. We present our series of children with complex vascular anomalies treated with sirolimus. Patients and Methods A retrospective review of 41 patients treated with sirolimus between January 2011 and December 2015 was performed: 15% (n = 6) had vascular tumors (4 kaposiform hemangioendotheliomas, 1 PTEN) and 85% (n = 35) had malformations (13 generalized lymphatic anomalies/Gorham-Stout diseases [GSD], 1 kaposiform lymphangiomatosis [KLA], 11 large lymphatic malformations (LMs) in critical areas, 2 lymphedemas, 4 venous malformations, and 4 aggressive arteriovenous malformations [AVM]). Several variables were collected: type of vascular anomaly, duration of treatment, dosage, response, and secondary effects. Results There was a female predominance (1.4:1). All patients received sirolimus, at initial dosage of 0.8 mg/m2/12 hour. Overall successful response rate was 80.4% of cases, presenting improvement in radiologic imaging and reduction of symptoms, at a median time of 10 weeks. Patients showing no response included four AVMs, one GSD, one LM, one KLA, and one unknown tumor. Sirolimus was well tolerated, even in neonates, with insignificant side effects. No patients had complete resolution and no patients worsened on therapy. Thirty patients remain under treatment at the present moment. Conclusion Sirolimus has become a new therapeutic option for patients with vascular anomalies that do not respond to other treatments. Unfortunately, important questions as what is the most appropriate dosage and for how long should the patient be treated remain unanswered. An international registry followed by customized controlled trials is mandatory to clarify the future of this therapy." @default.
- W2531935797 created "2016-10-21" @default.
- W2531935797 creator A5005942172 @default.
- W2531935797 creator A5034310029 @default.
- W2531935797 creator A5044939746 @default.
- W2531935797 creator A5051394299 @default.
- W2531935797 creator A5053459205 @default.
- W2531935797 creator A5056036257 @default.
- W2531935797 creator A5058834765 @default.
- W2531935797 creator A5070076286 @default.
- W2531935797 date "2016-10-10" @default.
- W2531935797 modified "2023-10-17" @default.
- W2531935797 title "Sirolimus in the Treatment of Vascular Anomalies" @default.
- W2531935797 doi "https://doi.org/10.1055/s-0036-1593383" @default.
- W2531935797 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27723921" @default.
- W2531935797 hasPublicationYear "2016" @default.
- W2531935797 type Work @default.
- W2531935797 sameAs 2531935797 @default.
- W2531935797 citedByCount "56" @default.
- W2531935797 countsByYear W25319357972017 @default.
- W2531935797 countsByYear W25319357972018 @default.
- W2531935797 countsByYear W25319357972019 @default.
- W2531935797 countsByYear W25319357972020 @default.
- W2531935797 countsByYear W25319357972021 @default.
- W2531935797 countsByYear W25319357972022 @default.
- W2531935797 countsByYear W25319357972023 @default.
- W2531935797 crossrefType "journal-article" @default.
- W2531935797 hasAuthorship W2531935797A5005942172 @default.
- W2531935797 hasAuthorship W2531935797A5034310029 @default.
- W2531935797 hasAuthorship W2531935797A5044939746 @default.
- W2531935797 hasAuthorship W2531935797A5051394299 @default.
- W2531935797 hasAuthorship W2531935797A5053459205 @default.
- W2531935797 hasAuthorship W2531935797A5056036257 @default.
- W2531935797 hasAuthorship W2531935797A5058834765 @default.
- W2531935797 hasAuthorship W2531935797A5070076286 @default.
- W2531935797 hasBestOaLocation W25319357971 @default.
- W2531935797 hasConcept C141071460 @default.
- W2531935797 hasConcept C142724271 @default.
- W2531935797 hasConcept C167135981 @default.
- W2531935797 hasConcept C181152851 @default.
- W2531935797 hasConcept C2775958455 @default.
- W2531935797 hasConcept C2776853793 @default.
- W2531935797 hasConcept C2777507709 @default.
- W2531935797 hasConcept C2777921159 @default.
- W2531935797 hasConcept C71924100 @default.
- W2531935797 hasConceptScore W2531935797C141071460 @default.
- W2531935797 hasConceptScore W2531935797C142724271 @default.
- W2531935797 hasConceptScore W2531935797C167135981 @default.
- W2531935797 hasConceptScore W2531935797C181152851 @default.
- W2531935797 hasConceptScore W2531935797C2775958455 @default.
- W2531935797 hasConceptScore W2531935797C2776853793 @default.
- W2531935797 hasConceptScore W2531935797C2777507709 @default.
- W2531935797 hasConceptScore W2531935797C2777921159 @default.
- W2531935797 hasConceptScore W2531935797C71924100 @default.
- W2531935797 hasIssue "01" @default.
- W2531935797 hasLocation W25319357971 @default.
- W2531935797 hasLocation W25319357972 @default.
- W2531935797 hasOpenAccess W2531935797 @default.
- W2531935797 hasPrimaryLocation W25319357971 @default.
- W2531935797 hasRelatedWork W2048633830 @default.
- W2531935797 hasRelatedWork W2149678707 @default.
- W2531935797 hasRelatedWork W2198776207 @default.
- W2531935797 hasRelatedWork W2531935797 @default.
- W2531935797 hasRelatedWork W2560966368 @default.
- W2531935797 hasRelatedWork W2803209405 @default.
- W2531935797 hasRelatedWork W2996802422 @default.
- W2531935797 hasRelatedWork W2999551596 @default.
- W2531935797 hasRelatedWork W348906656 @default.
- W2531935797 hasRelatedWork W4366086710 @default.
- W2531935797 hasVolume "27" @default.
- W2531935797 isParatext "false" @default.
- W2531935797 isRetracted "false" @default.
- W2531935797 magId "2531935797" @default.
- W2531935797 workType "article" @default.